Ketamine: evidence by condition

The evidence is strongest for treatment-resistant depression, where esketamine is FDA-approved and IV ketamine has been tested in large trials. For PTSD there are randomized trials but no approval. For bipolar depression, OCD and alcohol use disorder, studies are small and early. Esketamine's label states it has not been shown to prevent suicide.

How strong the evidence for ketamine is for treatment-resistant depression, suicidal thoughts, PTSD, bipolar depression, OCD and alcohol use disorder.

Strongest for treatment-resistant depression; promising but early almost everywhere else.

Key takeaways

Why rapid relief is not the whole story

Ketamine's antidepressant effect often appears within hours or days, which is what made it remarkable. But benefit commonly fades without a continued plan, long-term data are still limited, and response is not universal. A treatment's place depends on all of that, not only on speed.

What 'not shown to prevent suicide' means

Esketamine is approved to treat depressive symptoms in adults with major depression and acute suicidal thoughts or behavior, together with an oral antidepressant. Its label is explicit that effectiveness in preventing suicide, or in reducing suicidal thoughts or behavior, has not been demonstrated. It does not replace hospital care or a safety plan. If you are in crisis, call or text 988 in the U.S.

Reading early evidence

For conditions beyond depression, most studies are small, short and run in specialist centres. Small studies often show larger effects than later, larger trials confirm. 'Promising' is the honest word, and it is not the same as 'proven'.

Frequently asked questions

Does ketamine work for anxiety?

Anxiety disorders have been studied less than depression or PTSD, and we have not found evidence strong enough to place on this page. Well-established treatments for anxiety include CBT and certain medications.

Is ketamine a cure for depression?

No. It can bring rapid relief for some people with treatment-resistant depression, but effects often fade without ongoing care.

Related on Beiing

Sources

  1. SPRAVATO (esketamine) nasal spray, prescribing information - Janssen Pharmaceuticals, via DailyMed (U.S. National Library of Medicine)
  2. SPRAVATO approved in the U.S. as the first and only monotherapy for adults with treatment-resistant depression (21 January 2025) - Johnson & Johnson (manufacturer press release)
  3. Ketamine comparable to ECT for many patients with refractory depression (ELEKT-D trial, New England Journal of Medicine, 2023) - Psychiatric News (American Psychiatric Association)
  4. Repeated ketamine infusions reduce symptom severity in chronic PTSD (Feder et al., American Journal of Psychiatry, January 2021) - Icahn School of Medicine at Mount Sinai
  5. Kwan ATH, McIntyre RS, et al. Ketamine for the treatment of psychiatric disorders: a systematic review and meta-analysis. CNS Spectrums, 2024 - CNS Spectrums (Cambridge University Press)
  6. PubMed: randomized trials of ketamine in bipolar depression - U.S. National Library of Medicine
  7. ClinicalTrials.gov: ketamine studies - U.S. National Library of Medicine

Written by Beiing Editorial Team · Editorially reviewed by Beiing Editorial & Research Review · Published · Last reviewed . Editorial and research review by Beiing writers and researchers. This is not medical or clinical review, and no clinician signs off on our content.

Educational content only - not medical advice. In a crisis, call or text 988 (US) or your local emergency number. See crisis resources.